Chapter 12
The Cytoskeleton as a Modulator of Aging and Neurodegeneration

Konstantinos Kounakis and Nektarios Tavernarakis

1 Introduction

The cytoskeleton is a cellular entity, encompassing a multitude of filamentous proteins, forming structures that impart mechanical strength, allow intracellular transport and spatial organization, connect the cell to its environment, and generate forces that permit movement [1]. The ubiquitous nature of the cytoskeleton and the breadth of its functionality make it one of the most fascinating aspects of cellular biology, as well as one that is always worth considering when researching or discussing phenomena that affect the cells. In this review, we discuss the relevance of the cytoskeleton to the processes of aging and neurodegeneration, and provide examples that demonstrate its importance.

1.1 Components of the Cytoskeleton

Three types of cytoskeleton polymers have been defined: actin microfilaments, microtubules and intermediate filaments [1, 2]. We briefly describe their structure and function below.

K. Kounakis · N. Tavernarakis (✉)
Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece

Department of Basic Sciences, Medical School, University of Crete, Heraklion, Greece
e-mail: tavernarakis@imbb.forth.gr

P. C. Guest (ed.), *Reviews on Biomarker Studies in Aging and Anti-Aging Research*, Advances in Experimental Medicine and Biology 1178,
https://doi.org/10.1007/978-3-030-25650-0_12

1.1.1 Actin Microfilaments

Actin filaments (also commonly referred to as F-actin) are about 7 nm in diameter and consist of monomers of globular (G-actin) that interact head-to-tail with each other. G-actin can bind ATP, and this promotes its polymerization to F-actin. ATP is subsequently hydrolyzed to ADP. Actin filaments are polarized with a positive (+) and negative (−) end. Polymerization can occur at both ends but is significantly faster at the + end. The filaments can organize into higher order structures with the help of crosslinkers (Fig. 12.1). Highly aligned actin bundles are responsible for the formation of narrow cell protrusions, such as filopodia, while highly branched bundles take part in larger cellular movements, such as those that occur in phagocytosis. The polarity of the filaments also allows them to support a family of ATP driven motor proteins, the myosins, that contribute to actin network organization and force generation [1, 2].

In neurons, actin forms patches in the initial segment of the axon and at points along its length [3, 4]. It also forms, in association with the actin capping protein



Fig. 12.1 Organization of actin microfilaments. (**a**) G-actin polymerization. Actin monomers are loaded with ATP with the help of a protein with ATP exchange factor (AEF) activity. This induces their polymerization. (**b**) F-actin. (**c**) Larger scale F-actin organization facilitated by crosslinker proteins

adducin, a series of periodic rings spaced by spectrin that are wrapped around the axonal shaft [5]. Actin is also a major contributor the motility and guidance of the neuronal growth cone. The growth cone has three domains: the central (C), the peripheral (P) and the transition (T) domain [6]. Actin is rich in the P and T domain and its polymerization and recycling allows for the formation of exploratory filopodia. In addition, myosin 2 generates forces that assist in propelling the growth cone forward and steer it towards its targets. Inhibition of these functions does not prevent axonal growth but it significantly reduces its speed and abolishes its ability to respond to guidance cues [7, 8]. It can also act as the driving force for axonal branching, as actin filament patches can initiate the formation of protrusions that subsequently are invaded by microtubules to create new collateral branches that allow the same axon to interact with multiple targets [9]. Furthermore, actin has been connected to synaptic signaling, as it has been implicated in the regulation of synaptic vesicle pools, vesicle docking to the active zone, and even endocytic retrieval of vesicle membranes [10]. Finally, actin contributes to dendritic spine organization [11–13] and, in collaboration with microtubules and the receptor-associated protein gephyrin, contributes to postsynaptic receptor clustering [14].

In oligodendrocytes, the glial cells that are responsible for myelinating the axons of the CNS to facilitate fast action potential conduction, the actin cytoskeleton plays a critical role by allowing these cells to alter their morphology during development [15]. These cells possess protrusions with actin rich filopodia and lamellipodia. Actin in these structures is organized in a fashion mostly similar to growth cones [16]. It acts as a necessary driving force that allows these protrusions to extend towards their target axons and wrap around them [17–20]. Subsequently, actin depolymerization allows these protrusions to convert into sheets by reducing surface tension, enabling proper myelin spreading [19].

1.1.2 Microtubules

Microtubules (MTs) are cylindrical bundles of parallel protofilaments comprised of α- and β- tubulin. These bundles can have 10–16 individual filaments, with 13 being the most common. They have a typical diameter of about 25 nm. Both tubulins can bind GTP, which promotes polymerization, but eventually hydrolyze it to GDP, weakening their affinity. This leads to what is described as “dynamic instability”, as microtubules can switch between stable growth and rapid depolymerization. Microtubules are polarized, with a + and a − end. This polarity becomes particularly apparent during a phenomenon known as treadmilling, during which tubulin is simultaneously removed from the − end of the filament and polymerized to the + end (Fig. 12.2). This polarity also allows microtubules to support ATP driven motor proteins, the kinesins and dyneins, which are responsible for the guided transport of cellular cargo. Microtubules interact with a group of proteins known as MAPs (microtubule associated proteins) that influence their stability and interactions with other cellular components. A subset of MAPs, the +TIPs (plus-end-tracking proteins) interact specifically with growing microtubule ends. There are also − end



Fig. 12.2 Organization of microtubules. (**a**) GTP is loaded to α- and β- tubulin with the help of a protein with GTP Exchange Factor (GEF) activity. (**b**) A tubulin filament. (**c**) Microtubule structure and dynamics

capping proteins that can prevent depolymerization. Microtubule nucleation often needs to start at a Microtubule organization center (MTOC) where γ-tubulin interacts with α- and β- tubulin, providing a base for the start of filament extension [1, 2, 21]. The MTOC of mammalian cells is known as the centrosome. It consists of two perpendicular tubulin structures known as centrioles that are surrounded by a centrosomal matrix of proteins involved in microtubule nucleation, anchoring and release. The duplicated centrosome is responsible for the formation of the mitotic spindle, the microtubule structure that segregates chromatids during cell division [22].

In mature neurons, microtubules are arranged with the − end towards the cell body and the + end extending outwards, along the axon. They are discontinuous, with multiple start and stop sites [21]. In this context, there is evidence that microtubules cease to rely on the centrosomal MTOC for their organization [23, 24]. Axonal microtubules extend into growth cones, where they localize primarily in the C domain. However, they can extend even further and they are known to interact

with actin, particularly actin bundles that form filopodia in the P zone [6]. These microtubules have dynamic ends and are crucial to growth cone steering [25]. Outside of the growth cone, in cases of interstitial axonal branching formation, some axonal microtubules are reorganized and interact with the newly forming protrusion [26]. Microtubules also extend between the cell body and dendrites. In this case they adopt a mixed orientation, with + and − ends facing towards both directions [27].

1.1.3 Intermediate Filaments

Intermediate filaments (IFs) constitute a diverse family of cytoskeletal proteins that are expressed differentially across cell types. All of these proteins share structural similarity and organize in similar ways to provide mechanical strength and stability to most cell types, especially against tensile forces. IF subunits consist of a globular N-terminal head, an α-helical core and a variable C-terminal domain. Intermediate filament monomers tend to coalesce in pairs, forming parallel coiled coil dimers. Two antiparallel dimers can also associate to form a tetramer (Fig. 12.3). The higher scale organization depends on the tissue and the actual filament components but typically leads to a filamentous polymer of ~10 nm in diameter. Examples of IFs include keratin, vimentin, the lamins of the nuclear skeleton, α-internexin, peripherin, synemin, nestin or the light, medium and heavy neurofilaments (NF-L, NF-M and NF-H, respectively). Intermediate filaments are not polarized and therefore do not support molecular motors [1, 2, 28, 29].

Neuronal intermediate filaments (which will be referred as neurofilaments or NFs from now on) represent the main cytoskeletal element of mature neurons. They consist of NF-L, NF-M, NF-H and occasionally α-internexin and peripherin, with



Fig. 12.3 Intermediate filament organization. (**a**) Monomer. (**b**) Dimer of parallel monomers. (**c**) Tetramer of antiparallel dimers

the actual composition varying by organism or even stage of development. The NF-M and NF-H C-terminal domains are notable for the presence of a large number of lysine-serine-proline (KSP) repeats that represent targets for regulatory phosphorylation. Neurofilaments reside in axons and act as regulators of axonal caliber, which has implications in myelin thickness and the rate of axonal conduction. They are also associated with axonal growth and regeneration [2, 29, 30].

2 The Importance of the Cytoskeleton to Aging and Neurodegeneration

2.1 Cytoskeleton and Organismal Aging

There is ample experimental evidence connecting the cytoskeleton with the processes of cellular and organismal aging. In yeast, actin has emerged as a regulator of lifespan by regulating the inheritance of mitochondria. During budding, actin cables create a retrograde flow from the bud towards the mother cell, driven by polymerization and myosin activity. This flow pushes mitochondria away from the bud, forcing them to "swim upstream" and ensuring that only healthy mitochondria can reach the new cell, granting it a longer lifespan and healthspan [31, 32].

In C. elegans, the actin cytoskeleton has been observed to deteriorate with aging. HSF-1, the master regulator of the heat shock response that provides thermotolerance and also contributes to organismal longevity, has been shown to act against this deterioration. This effect is mostly mediated through the upregulation of the expression of the calcium binding protein PAT-10. Most notably, loss of pat-10 is sufficient to decrease organismal lifespan and thermotolerance, while overexpression enhances thermotolerance and promotes longevity [33, 34].

In mammals and particularly in humans, oocyte fertility is reduced in aging. This is in part due to deterioration of meiotic spindle integrity. Spindle microtubules lose their ability to accurately interact with meiotic chromosomes and separate them, thus causing aneuploidies. The deterioration of the spindle can be attributed to the reduced activity of enzymes that are responsible for centrosome and microtubule maintenance [22, 35]. Centrosome defects have also been proposed as a possible explanation for the age-related decline of stem cell division [36].

The myelin sheath is crucial to adult neuron performance. Unfortunately, even healthy aging is accompanied by the emergence of defects in myelin composition and structure [37–39]. Thus maintenance mechanisms need to be activated to protect the axons. In the case of CNS oligodendrocytes, there is evidence indicating that the cytoskeleton is a fundamental constituent of these processes. Septins, a family of cytoskeleton associated scaffold proteins, have been shown to form filaments along with anillin in mice that support the myelin sheath and loss of these proteins leads to defects in myelin structure [40]. Additionally, it has been shown that de novo myelination pathways in the CNS remain active in adulthood through

new oligodendrocytes [41–43], the maturation of which is guided by cytoskeleton dynamics. This de novo myelination has been mostly associated with plasticity related adaptations but could also participate in maintenance.

In humans, aging is associated with increased aortic stiffness. This is often considered to preclude myocardial infarction, renal disease or even cognitive decline. A significant part of this aortic stiffness is attributed to vascular smooth muscle cells and particularly to their non-muscle actin cytoskeleton that is responsible for their connection to the extracellular matrix. Decoy peptides that inhibit actin polymerization or the interaction of the actin associated proteins talin and vinculin have been shown to be a potential method for counteracting aortic stiffness [44].

Another issue that emerges with human aging is the deterioration of heart health. Heart failure in particular is one of the most prominent causes of death and disability in the elderly [45]. Actin is critical to heart health, as actin fibers constitute a major component of sarcomers, the mechanical units that drive cardiomyocyte contraction [46]. Experiments in mice and rats have shown a conserved activation of actin remodeling by vinculin during aging. Further experiments in Drosophila have suggested that this is an anti-aging mechanism that improves heart function and overall organismal lifespan [47]. Actin is also relevant to heart health due to its association with the proliferative capacity of cardiac fibroblasts. Aging fibroblasts exhibit reduced levels of the LOX-1 receptor, lose their proliferative capacity and exhibit a disorganized actin network. Restoration of LOX-1 levels re-establishes fibroblast proliferative potential and reinstates actin organization [48].

2.2 Cytoskeleton and Neurodegeneration

Considering the prominent presence and important functionality of cytoskeletal proteins in neurons, it comes as no surprise that they have also been heavily implicated over the years in processes underlying their dysfunction. Below, we discuss experimental data that connects the cytoskeleton to neurodegenerative diseases, as well as injury induced neurodegeneration.

2.2.1 Tau Associated Pathologies

Alzheimer's disease (AD) is characterized by extracellular deposits of Aβ peptides and intracellular filamentous aggregates of Tau, a major microtubule associated protein [49–52]. Beyond AD, Tau aggregation has emerged as a common form of phenomenon in more than 20 different types of neurological disease, including Pick's disease, progressive supranuclear palsy, chronic traumatic encelopathy, argyrophilic grain disease, frontotemporal dementia with parkinsonism-17, corticobasal degeneration and Parkinson's disease (PD) [49, 53]. In the human brain, Tau has six isoforms with either 3 or 4 microtubule binding repeats at its C-terminal domain (3R and 4R Tau respectively) [49, 54, 55]. The protein is typically a dipole but

post-translational modification, especially phosphorylation, can affect its charges and disrupt its ability to bind microtubules [56–58]. In addition to its microtubule binding abilities, it has been shown to interact with the plasma membrane [59]. It is also capable of interacting with actin, induce its polymerization and promote microtubule and actin co-alignment [60].

Tau assembles into filaments through its repeats forming a cross-beta structure. Thus, the microtubule binding regions are trapped in the core of the aggregate, rendering physiological interaction with microtubules impossible [61–64]. Tau aggregates are commonly referred to as Neurofibrillary Tangles (NFTs), but their actual morphology can vary across different diseases, leading to their sub-characterization into paired helical filaments (PHFs), straight filaments (SFs) and twisted ribbon-like lilaments (TRFs) [49, 51]. Tau is abnormally hyperphosphorylated in all of its aggregates. This has led to the belief that phosphorylation is toxic and induces Tau aggregation. However, this might not be the case as human tauopathies have not been linked to defects in kinases or phosphatases, and kinase inhibition has not been shown to be an effective treatment option [49, 51]. Furthermore, there is evidence of Tau phosphorylation acting in a benign fashion in the process of hibernation [65, 66], without fibril formation and with reversibility.

There are several possible explanations on the causes of Tau associated neuropathology; Tau aggregation could lead to an effective LoF phenotype by preventing the protein form exercising its normal roles [67]. For instance loss of Tau in mouse models of AD (over-expressing mutant APP, the precursor of the Aβ peptide) aggravated neurodegeneration and exhibited axonal swellings full of cellular debris and mislocalized organelles, vesicles and even presynaptic terminal components [68]. In addition, Tau KO mice exhibit intracellular iron accumulation, substantia nigra neurodegeneration, brain atrophy and parkinsonism. Supplementation with an iron chelator rescued this phenotype. These observations were attributed to reduced transport of APP onto the neuronal membrane (APP in conjunction with ferroportin acts as the sole iron export system in neurons) due to the altered microtubule dynamics that arise from lack of Tau [69]. Another indication supporting this idea is the observation that microtubule stabilizing drug treatment has had some effectiveness in ameliorating tauopathy [70–72]. An alternate explanation could be that Tau (normal, mutant and/or phosphorylated) represents a toxic threat to cells in a gain of function (GoF) fashion. The protein has, for instance, been implicated in the disruption of mitochondria through the induction of mitochondrial fusion, inhibition of mitophagy and a reduction of ATP production [73, 74]. There are indications suggesting that a GoF threat might arise from non-filamentous forms of Tau [51], as experiments have demonstrated that truncated/cleaved Tau can be toxic [75, 76]. In addition, neurodegeneration can occur before or without Tau filament formation [77, 78] and tangle formation can persist in rescued animal models [79]. In the latter case, NFT formation might act as an attempt from the cell to quarantine dangerous Tau forms. Arguably, it is possible that both explanations are true on a disease by disease basis, or even simultaneously, with aggregation acting as the “lesser evil” that initially protects neuronal cells from toxicity but eventually ends up being deleterious through dysregulation of the cytoskeleton or other effects.

The aforementioned Tau-actin interaction [60] might have a functional implication in neurodegenerative disease, as experiments in Drosophila melanogaster and have shown that mutant forms of Tau associated with human tauopathies are capable of inducing the formation of actin rich structures resembling Hirano bodies (actin aggregates that occur in human patients). Actin was necessary for Tau toxicity in these instances. Tau phosphorylation, as well as transgenic Aβ42 expression, exacerbated actin aggregation and neuronal death [80]. Recently it was reported that tau can accumulate and form tangles in the medial temporal lobe and particularly in the entorhinal cortex as a pure consequence of normal "healthy" aging indicating a possible mechanism for the aging-associated loss of episodic memory [81].

2.2.2 Other Microtubule Associated Pathologies

The implication of microtubules in neurodegenerative disease extends beyond the role of Tau. Part of the neurotoxicity in Huntington's disease (HD) can be attributed to defects in microtubule based axonal transport, and MT stabilizing acetylation is potentially beneficial [82]. Very similar observations have been made in a model of Charcot-Marie-Tooth disease (CMT) [83]. Experiments in a PD model have shown that intracellular transport could be disrupted due to the reduction of microtubule dynamics, and that this might preclude mitochondrial damage and caspase 3 activation [84]. Disrupted mitochondrial dynamics, along with reduced levels of MAP expression, can also be observed in amyotrophic lateral sclerosis (ALS) patients and models, and pharmacological MT stabilization can delay the progression of the disease in mice [85–87].

2.2.3 Actin Associated Pathologies

ALS is a neurodegenerative disorder associated with the loss of motor neurons in the cerebral cortex, the brainstem, and the ventral horn of the spinal cord [88]. The disease is mainly linked with alterations in genes such as superoxide dismutase 1 (SOD1), fused in sarcoma (FUS) and TAR DNA binding protein (TARDBP / TDP-43) [89]. Spinal muscular atrophy (SMA) is a disorder with phenotypical similarity to ALS that exhibits motor neuron loss exclusively in the ventral horn of the spinal cord [88]. SMA is attributed to loss of function (LoF) of the survival of motor neuron 1 gene (SMN1) [90]. Both ALS and SMA have been linked with altered cytoskeletal dynamics or mutations in known regulators of the cytoskeleton [91–97]. Notably, the actin regulators profilins have been implicated in both diseases [93, 96–98]. Profilins are a family of proteins that can bind monomeric G actin and facilitate the exchange of ADP for ATP. Depending on the cellular conditions, profilins have been suggested to act as either a promoter of actin polymerization and F-actin stabilizer, or as a sequester of G-actin and F-actin destabilizer [88, 99]. Profilin binding activity can be inhibited through phosphorylation by the RhoA kinase (ROCK), an important regulator of actin dynamics [100, 101]. It has been

shown that SMN1 binding to profilin 2 reduces its inhibitory effects and promotes actin polymerization [93]. It has also been suggested that this binding protects profilin from ROCK phosphorylation and that the source of cytoskeletal defects in SMA is the loss of this protection [88]. In ALS, profilin 1 has been suggested to contribute to disease pathology through the formation of TDP-43 associated aggregates [97, 102, 103], through loss of its ability to interact with stress granules [104], or through dysregulation of actin dynamics [105, 106]. It is worth mentioning that profilin has also been shown to interact with the polyglutamate protein Huntingtin and inhibit its aggregation. The prevention of profilin inhibition by ROCK has also been demonstrated as a potential therapeutic approach for HD [101]. Beyond its aforementioned potential association with Tau, another connection of actin with AD pathology was revealed recently. The actin cytoskeleton was shown to be compromised in transgenic mouse models early in disease progression in conjunction with dendritic spine effects and a decline of AMPA signaling [107].

Microglia can act as a line of defense against AD by migrating towards extracellular Aβ42 aggregates, binding them and phagocytosing them. However during aging, Nogo/Ngr signaling reduces the ability of microglia to migrate and adhere to Aβ42 through Rho-GTPases that regulate actin dynamics and end up preventing protrusion extension and cell polarization [108]. On the other hand, the cytoskeleton might also have an inhibitory role in this interaction, as it has been reported that cytosolic phospholipase A2 (cPLA2), a factor that mediates the Aβ-induced response in glial cells, acts to reduce the cytoskeletal-membrane connectivity that represents a physical barrier against Aβ endocytosis [109].

Alterations in actin dynamics may also play a role in PD, as a-syn has been shown to inhibit cofilin, an actin destabilizer, in experimental models and patients. This leads to actin overstabilization, with potential negative implications for synaptic signaling [110]. Cdc42 is a Rho-GTPase that is involved in the regulation of actin dynamics. Some variants of variants of CMT have been associated with a mutation in Frabin, the GTP exchange factor of Cdc42 [111, 112].

2.2.4 Neurofilament Associated Pathologies

Neurofilaments have also been associated with neurodegenerative disease. Abnormal neurofilament aggregation has been observed in various disorders, such as AD, PD, CMT and ALS. It seems to be connected with deviations from the exact correct NF component stoichiometry, as it can occur in response to both down-regulation or up-regulation of individual NF genes [113–115].

In AD, neurofilaments are another major component of Tau NFTs [116]. In these tangles, they adopt a paired helical filament conformation [117], and exhibit extensive levels of phosphorylation [118].

Neurofilaments are also a primary component of the Lewy bodies, the characteristic protein inclusions of PD [119, 120]. They are extensively phosphorylated in this instance as well [121]. Patient tissues exhibit down-regulation of NF-L and NF-H expression [122]. Mutations in the gene that codes NF-L have emerged as a

cause for CMT. These mutations lead to defects of axonal transport, neurofilament disorganization, and usually aggregation [123–131]. Some of the NF-L mutations that cause CMT lead to neurofilament aggregation due to the abolition of protective phosphorylation [129–132].

ALS is characterized by intraneuronalaxonal NF aggregation [133–135]. This is also the case in mice expressing mutant human SOD1, the gene mostly associated with familial cases of ALS [136]. This aggregation might be dispensable for the eventual progression of the disease [137] but its reduction might still be somewhat beneficial. Perhaps unexpectedly, overexpression of NF-H [138–140], or NF-L [138] or downregulation of NF-L [141] were all successful in imparting a partial protective effect that is attributed to a redirection of NF accumulation from the axon to the cell body/perikaryon. The exact mechanism of this protection is, however, uncertain.

2.2.5 Neurodegeneration Due to Injury

Injured axons of CNS neurons degenerate, in a process known as Wallerian degeneration. Fragmentation of microtubules is possibly the earliest step in this process [142]. Axons that are retracting due to injury exhibit a disorganized microtubule network [143]. In cases where axonal regeneration is possible (such as the peripheral nervous system), it is driven by microtubules and requires tubulin deacetylation, a modification that decreases their stability [144, 145]. The levels of expressed and axonally transported neurofilaments are also reduced, and are only restored in axons that can regenerate [146–154]. Microtubule destabilization accompanied by energy depletion precludes neurofilament defects, mitochondrial swelling and axonal degeneration. Artificial energy repletion is effective at stopping this process [155]. Dendrites also degenerate after injury. Experiments in D. Melanogaster showed that this requires microtubule severance by the ATPase fidgetin [156].

3 Conclusions

Despite decades of research, our knowledge on the cytoskeleton remains incomplete. There are still numerous questions that need to be addressed regarding cytoskeletal contributions to pathology. In this regard, the cytoskeleton represents a clear challenge for future research, and for the development of potential therapeutic strategies relevant to aging and neurodegeneration.

Acknowledgements We apologize to those colleagues, whose work could not be referenced owing to space limitations. Work in the authors' laboratory is funded by grants from the European Research Council (ERC – GA695190 – MANNA, ERC – GA737599 – NeuronAgeScreen), the European Commission Framework Programmes, and the Greek Ministry of Education. Konstantinos Kounakis is supported by the Greek Foundation of Research and Innovation (ELIDEK).

References

1. Fletcher DA, Mullins RD (2010) Cell mechanics and the cytoskeleton. Nature 463(7280): 485–492
2. Eira J, Silva CS, Sousa MM, Liz MA (2016) The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders. Prog Neurobiol 141:61–82
3. Spillane M, Ketschek A, Jones SL, Korobova F, Marsick B, Lanier L et al (2011) The actin nucleating Arp2/3 complex contributes to the formation of axonal filopodia and branches through the regulation of actin patch precursors to filopodia. Dev Neurobiol 71(9):747–758
4. Watanabe K, Al-Bassam S, Miyazaki Y, Wandless TJ, Webster P, Arnold DB (2012) Networks of polarized actin filaments in the axon initial segment provide a mechanism for sorting axonal and dendritic proteins. Cell Rep 2(6):1546–1553
5. Xu K, Zhong G, Zhuang X (2013) Actin, spectrin, and associated proteins form a periodic cytoskeletal structure in axons. Science 339(6118):452–456
6. Schaefer AW, Kabir N, Forscher P (2002) Filopodia and actin arcs guide the assembly and transport of two populations of microtubules with unique dynamic parameters in neuronal growth cones. J Cell Biol 158(1):139–152
7. Gomez TM, Letourneau PC (2014) Actin dynamics in growth cone motility and navigation. J Neurobiol 129(2):221–234
8. Marsh L, Letourneau PC (1984) Growth of neurites without filopodial or lamellipodial activity in the presence of cytochalasin B. J Cell Biol 99(6):2041–2047
9. Gallo G (2011) The cytoskeletal and signaling mechanisms of axon collateral branching. Dev Neurobiol 71(3):201–220
10. Cingolani LA, Goda Y (2008) Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. Nat Rev Neurosci 9(5):344–356
11. Cohen RS, Chung SK, Pfaff DW (1985) Immunocytochemical localization of actin in dendritic spines of the cerebral cortex using colloidal gold as a probe. Cell Mol Neurobiol 5(3):271–284
12. Matus A, Ackermann M, Pehling G, Byers HR, Fujiwara K (1982) High actin concentrations in brain dendritic spines and postsynaptic densities. Proc Natl Acad Sci U S A 79(23):7590–7594
13. Korobova F, Svitkina T (2010) Molecular architecture of synaptic actin cytoskeleton in hippocampal neurons reveals a mechanism of dendritic spine morphogenesis. Mol Biol Cell 21(1):165–176
14. Kirsch J, Betz H (1995) The postsynaptic localization of the glycine receptor-associated protein gephyrin is regulated by the cytoskeleton. J Neurosci 15(6):4148–4156
15. Seixas AI, Azevedo MM, de Faria JP, Fernandes D, Mendes Pinto I, Relvas JB (2019) Evolvability of the actin cytoskeleton in oligodendrocytes during central nervous system development and aging. Cell Mol Life Sci 76(1):1–11
16. Fox MA, Afshari FS, Alexander JK, Colello RJ, Fuss B (2006) Growth conelike sensorimotor structures are characteristic features of postmigratory, premyelinating oligodendrocytes. Glia 53(5):563–566
17. Song J, Goetz BD, Baas PW, Duncan ID (2001) Cytoskeletal reorganization during the formation of oligodendrocyte processes and branches. Mol Cell Neurosci 17(4):624–636
18. Azevedo MM, Domingues HS, Cordelieres FP, Sampaio P, Seixas AI, Relvas JB (2018) Jmy regulates oligodendrocyte differentiation via modulation of actin cytoskeleton dynamics. Glia 66(9):1826–1844
19. Nawaz S, Sanchez P, Schmitt S, Snaidero N, Mitkovski M, Velte C et al (2015) Actin filament turnover drives leading edge growth during myelin sheath formation in the central nervous system. Dev Cell 34(2):139–151
20. Zuchero JB, Fu MM, Sloan SA, Ibrahim A, Olson A, Zaremba A et al (2015) CNS myelin wrapping is driven by actin disassembly. Dev Cell 34(2):152–167

21. Penazzi L, Bakota L, Brandt R (2016) Microtubule dynamics in neuronal development, plasticity, and neurodegeneration. Int Rev Cell Mol Biol 321:89–169
22. Schatten H, Sun QY (2018) Functions and dysfunctions of the mammalian centrosome in health, disorders, disease, and aging. Histochem Cell Biol 150(4):303–325
23. Nguyen MM, Stone MC, Rolls MM (2011) Microtubules are organized independently of the centrosome in Drosophila neurons. Neural Dev 6:38. https://doi.org/10.1186/1749-8104-6-38
24. Stiess M, Maghelli N, Kapitein LC, Gomis-Ruth S, Wilsch-Brauninger M, Hoogenraad CC et al (2010) Axon extension occurs independently of centrosomal microtubule nucleation. Science 327(5966):704–707
25. Challacombe JF, Snow DM, Letourneau PC (1997) Dynamic microtubule ends are required for growth cone turning to avoid an inhibitory guidance cue. J Neurosci 17(9):3085–3095
26. Dent EW, Callaway JL, Szebenyi G, Baas PW, Kalil K (1999) Reorganization and movement of microtubules in axonal growth cones and developing interstitial branches. J Neurosci 19(20):8894–8908
27. Conde C, Caceres A (2009) Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 10(5):319–332
28. Herrmann H, Aebi U (2016) Intermediate filaments: structure and assembly. Cold Spring Harb Perspect Biol 8(11):pii: a018242. https://doi.org/10.1101/cshperspect.a018242
29. Perrot R, Berges R, Bocquet A, Eyer J (2008) Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol 38(1):27–65
30. Zhu Q, Couillard-Despres S, Julien JP (2013) Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp Neurol 148(1):299–316
31. Higuchi R, Vevea JD, Swayne TC, Chojnowski R, Hill V, Boldogh IR et al (2013) Actin dynamics affect mitochondrial quality control and aging in budding yeast. Curr Biol 23(23):2417–2422
32. Higuchi-Sanabria R, Vevea JD, Charalel JK, Sapar ML, Pon LA (2016) The transcriptional repressor Sum1p counteracts Sir2p in regulation of the actin cytoskeleton, mitochondrial quality control and replicative lifespan in Saccharomyces cerevisiae. Microb Cell 3(2):79–88
33. Baird NA, Douglas PM, Simic MS, Grant AR, Moresco JJ, Wolff SC et al (2014) HSF-1-mediated cytoskeletal integrity determines thermotolerance and life span. Science 346(6207):360–363
34. Higuchi-Sanabria R, Paul Rd JW, Durieux J, Benitez C, Frankino PA, Tronnes SU et al (2018) Spatial regulation of the actin cytoskeleton by HSF-1 during aging. Mol Biol Cell 29(21):2522–2527
35. Wang ZB, Schatten H, Sun QY (2011) Why is chromosome segregation error in oocytes increased with maternal aging? Physiology (Bethesda) 26(5):314–325
36. Cheng J, Turkel N, Hemati N, Fuller MT, Hunt AJ, Yamashita YM (2008) Centrosome misorientation reduces stem cell division during ageing. Nature 456(7222):599–604
37. Liu H, Yang Y, Xia Y, Zhu W, Leak RK, Wei Z et al (2017) Aging of cerebral white matter. Ageing Res Rev 34:64–76
38. Stahon KE, Bastian C, Griffith S, Kidd GJ, Brunet S, Baltan S (2016) Age-related changes in axonal and mitochondrial ultrastructure and function in white matter. J Neurosci 36(39):9990–10001
39. Peters A, Kemper T (2012) A review of the structural alterations in the cerebral hemispheres of the aging rhesus monkey. Neurobiol Aging 33(10):2357–2372
40. Patzig J, Erwig MS, Tenzer S, Kusch K, Dibaj P, Mobius W et al (2016) Septin/anillin filaments scaffold central nervous system myelin to accelerate nerve conduction. Elife 5:pii: e17119. https://doi.org/10.7554/eLife.17119
41. Young KM, Psachoulia K, Tripathi RB, Dunn SJ, Cossell L, Attwell D et al (2013) Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling. Neuron 77(5):873–885
42. Hill RA, Li AM, Grutzendler J (2018) Lifelong cortical myelin plasticity and age-related degeneration in the live mammalian brain. Nat Neurosci 21(5):683–695

43. Hughes EG, Orthmann-Murphy JL, Langseth AJ, Bergles DE (2018) Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex. Nat Neurosci 21(5):696–706
44. Nicholson CJ, Singh K, Saphirstein RJ, Gao YZ, Li Q, Chiu JG et al (2018) Reversal of aging-induced increases in aortic stiffness by targeting cytoskeletal protein-protein interfaces. J Am Heart Assoc 7(15):pii: e008926. https://doi.org/10.1161/JAHA.118.008926
45. Biernacka A, Frangogiannis NG (2011) Aging and cardiac fibrosis. Aging Dis 2(2):158–173
46. Thompson BR, Metzger JM (2014) Cell biology of sarcomeric protein engineering: disease modeling and therapeutic potential. Anat Rec (Hoboken) 297(9):1663–1669
47. Kaushik G, Spenlehauer A, Sessions AO, Trujillo AS, Fuhrmann A, Fu Z et al (2015) Vinculin network-mediated cytoskeletal remodeling regulates contractile function in the aging heart. Sci Transl Med 7(292):292ra99. https://doi.org/10.1126/scitranslmed.aaa5843
48. Wang X, Khaidakov M, Ding Z, Dai Y, Mercanti F, Mehta JL (2013) LOX-1 in the maintenance of cytoskeleton and proliferation in senescent cardiac fibroblasts. J Mol Cell Cardiol 60:184–190
49. Chang HY, Sang TK, Chiang AS (2018) Untangling the tauopathy for Alzheimer's disease and parkinsonism. J Biomed Sci 25(1):54. https://doi.org/10.1186/s12929-018-0457-x
50. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7(8):656–664
51. Goedert M, Eisenberg DS, Crowther RA (2017) Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci 40:189–210
52. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121–1159
53. Williams DR (2006) Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J 36(10):652–660
54. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA (1989) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 8(2):393–399
55. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3(4):519–526
56. Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G (2014) Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci 15(3):4671–4713
57. Jho YS, Zhulina EB, Kim MW, Pincus PA (2010) Monte carlo simulations of tau proteins: effect of phosphorylation. Biophys J 99(8):2387–2397
58. Fischer D, Mukrasch MD, Biernat J, Bibow S, Blackledge M, Griesinger C et al (2009) Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules. Biochemistry 48(42):10047–10055
59. Brandt R, Leger J, Lee G (1995) Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 131(5):1327–1340
60. Elie A, Prezel E, Guerin C, Denarier E, Ramirez-Rios S, Serre L et al (2015) Tau co-organizes dynamic microtubule and actin networks. Sci Rep 5:9964. https://doi.org/10.1038/srep09964
61. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A 85(11):4051–4055
62. Wischik CM, Novak M, Thogersen HC, Edwards PC, Runswick MJ, Jakes R et al (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85(12):4506–4510
63. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA (1988) Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85(13):4884–4888

64. Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA (2003) Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A 100(15):9034–9038
65. Arendt T, Bullmann T (2013) Neuronal plasticity in hibernation and the proposed role of the microtubule-associated protein tau as a "master switch" regulating synaptic gain in neuronal networks. Am J Physiol Regul Integr Comp Physiol 305(5):R478–R489
66. Su B, Wang X, Drew KL, Perry G, Smith MA, Zhu X (2008) Physiological regulation of tau phosphorylation during hibernation. J Neurochem 105(6):2098–2108
67. Brandt R (2001) Cytoskeletal mechanisms of neuronal degeneration. Cell Tissue Res 305(2):255–265
68. Dawson HN, Cantillana V, Jansen M, Wang H, Vitek MP, Wilcock DM et al (2010) Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 169(1):516–531
69. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK et al (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18(2):291–295
70. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS et al (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 32(11):3601–3611
71. Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH et al (2012) Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci 32(21):7137–7145
72. Graham WV, Bonito-Oliva A, Sakmar TP (2017) Update on Alzheimer's disease therapy and prevention strategies. Annu Rev Med 68:413–430
73. Li XC, Hu Y, Wang ZH, Luo Y, Zhang Y, Liu XP et al (2016) Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins. Sci Rep 6:24756. https://doi.org/10.1038/srep24756
74. Hu Y, Li XC, Wang ZH, Luo Y, Zhang X, Liu XP et al (2016) Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin. Oncotarget 7(14):17356–17368
75. Rao MV, McBrayer MK, Campbell J, Kumar A, Hashim A, Sershen H et al (2014) Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci 34(28):9222–9234
76. Afreen S, Riherd Methner DN, Ferreira A (2017) Tau45-230 association with the cytoskeleton and membrane-bound organelles: functional implications in neurodegeneration. Neuroscience 362:104–117
77. Ozcelik S, Sprenger F, Skachokova Z, Fraser G, Abramowski D, Clavaguera F et al (2016) Co-expression of truncated and full-length tau induces severe neurotoxicity. Mol Psychiatry 21(12):1790–1798
78. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M et al (2001) Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293(5530):711–714
79. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M et al (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733):476–481
80. Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT et al (2007) Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol 9(2):139–148
81. Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K et al (2018) Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging. J Neurosci 38(3):530–543

82. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S et al (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 27(13):3571–3583
83. d'Ydewalle C, Krishnan J, Chiheb DM, Van Damme P, Irobi J, Kozikowski AP et al (2011) HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 17(8):968–974
84. Cartelli D, Ronchi C, Maggioni MG, Rodighiero S, Giavini E, Cappelletti G (2010) Microtubule dysfunction precedes transport impairment and mitochondria damage in MPP+ -induced neurodegeneration. J Neurochem 115(1):247–258
85. Kikuchi H, Doh-ura K, Kawashima T, Kira J, Iwaki T (1999) Immunohistochemical analysis of spinal cord lesions in amyotrophic lateral sclerosis using microtubule-associated protein 2 (MAP2) antibodies. Acta Neuropathol 97(1):13–21
86. Farah CA, Nguyen MD, Julien JP, Leclerc N (2003) Altered levels and distribution of microtubule-associated proteins before disease onset in a mouse model of amyotrophic lateral sclerosis. J Neurochem 84(1):77–86
87. Fanara P, Banerjee J, Hueck RV, Harper MR, Awada M, Turner H et al (2007) Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis. J Biol Chem 282(32):23465–23472
88. Hensel N, Claus P (2018) The actin cytoskeleton in SMA and ALS: how does it contribute to motoneuron degeneration? Neuroscientist 24(1):54–72
89. Renton AE, Chio A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17(1):17–23
90. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1):155–165
91. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS et al (2002) A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 29(2):166–173
92. Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M et al (2001) The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29(2):160–165
93. Sharma A, Lambrechts A, Hao le T, Le TT, Sewry CA, Ampe C et al (2005) A role for complexes of survival of motor neurons (SMN) protein with gemins and profilin in neurite-like cytoplasmic extensions of cultured nerve cells. Exp Cell Res 309(1):185–197
94. van Bergeijk J, Rydel-Konecke K, Grothe C, Claus P (2007) The spinal muscular atrophy gene product regulates neurite outgrowth: importance of the C terminus. FASEB J 21(7):1492–1502
95. Oprea GE, Krober S, McWhorter ML, Rossoll W, Muller S, Krawczak M et al (2008) Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320(5875):524–527
96. Nolle A, Zeug A, van Bergeijk J, Tonges L, Gerhard R, Brinkmann H et al (2011) The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. Hum Mol Genet 20(24):4865–4878
97. Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K et al (2012) Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 488(7412):499–503
98. Giesemann T, Rathke-Hartlieb S, Rothkegel M, Bartsch JW, Buchmeier S, Jockusch BM et al (1999) A role for polyproline motifs in the spinal muscular atrophy protein SMN. Profilins bind to and colocalize with smn in nuclear gems. J Biol Chem 274(53):37908–37914
99. Jockusch BM, Murk K, Rothkegel M (2007) The profile of profilins. Rev Physiol Biochem Pharmacol 159:131–149
100. Da Silva JS, Medina M, Zuliani C, Di Nardo A, Witke W, Dotti CG (2003) RhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability. J Cell Biol 162(7):1267–1279

101. Shao J, Welch WJ, Diprospero NA, Diamond MI (2008) Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol 28(17):5196–5208
102. Smith BN, Vance C, Scotter EL, Troakes C, Wong CH, Topp S et al (2015) Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. Neurobiol Aging 36(3):1602.e17–1602.e27. https://doi.org/10.1016/j.neurobiolaging.2014.10.032
103. Tanaka Y, Hasegawa M (2016) Profilin 1 mutants form aggregates that induce accumulation of prion-like TDP-43. Prion 10(4):283–289
104. Figley MD, Bieri G, Kolaitis RM, Taylor JP, Gitler AD (2014) Profilin 1 associates with stress granules and ALS-linked mutations alter stress granule dynamics. J Neurosci 34(24):8083–8097
105. Fil D, DeLoach A, Yadav S, Alkam D, MacNicol M, Singh A et al (2017) Mutant profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum Mol Genet 26(4):686–701
106. Yang C, Danielson EW, Qiao T, Metterville J, Brown RH Jr, Landers JE et al (2016) Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity. Proc Natl Acad Sci U S A 113(41):E6209–E6218
107. Baglietto-Vargas D, Prieto GA, Limon A, Forner S, Rodriguez-Ortiz CJ, Ikemura K et al (2018) Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease. Aging Cell 6:e12791. https://doi.org/10.1111/acel.12791
108. Fang Y, Wang J, Yao L, Li C, Wang J, Liu Y et al (2018) The adhesion and migration of microglia to beta-amyloid (Abeta) is decreased with aging and inhibited by Nogo/NgR pathway. J Neuroinflammation 15(1):210. https://doi.org/10.1186/s12974-018-1250-1
109. Teng T, Dong L, Ridgley DM, Ghura S, Tobin MK, Sun GY et al (2019) Cytosolic phospholipase A2 facilitates oligomeric amyloid-beta peptide association with microglia via regulation of membrane-cytoskeleton connectivity. Mol Neurobiol 56(5):3222–3234. https://doi.org/10.1007/s12035-018-1304-5
110. Bellani S, Mescola A, Ronzitti G, Tsushima H, Tilve S, Canale C et al (2014) GRP78 clustering at the cell surface of neurons transduces the action of exogenous alpha-synuclein. Cell Death Differ 21(12):1971–1983
111. Delague V, Jacquier A, Hamadouche T, Poitelon Y, Baudot C, Boccaccio I et al (2007) Mutations in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot-Marie-Tooth type 4H. Am J Hum Genet 81(1):1–16
112. Stendel C, Roos A, Deconinck T, Pereira J, Castagner F, Niemann A et al (2007) Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4. Am J Hum Genet 81(1):158–164
113. Xu Z, Cork LC, Griffin JW, Cleveland DW (1993) Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 73(1):23–33
114. Wong PC, Marszalek J, Crawford TO, Xu Z, Hsieh ST, Griffin JW et al (1995) Increasing neurofilament subunit NF-M expression reduces axonal NF-H, inhibits radial growth, and results in neurofilamentous accumulation in motor neurons. J Cell Biol 130(6):1413–1422
115. Cote F, Collard JF, Julien JP (1993) Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 73(1):35–46
116. Ksiezak-Reding H, Dickson DW, Davies P, Yen SH (1987) Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc Natl Acad Sci U S A 84(10):3410–3414
117. Selkoe DJ, Ihara Y, Salazar FJ (1982) Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Science 215(4537):1243–1245
118. Wang J, Tung YC, Wang Y, Li XT, Iqbal K, Grundke-Iqbal I (2001) Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett 507(1):81–87

119. Goldman JE, Yen SH, Chiu FC, Peress NS (1983) Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 221(4615):1082–1084
120. Galloway PG, Mulvihill P, Perry G (1992) Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 140(4):809–822
121. Forno LS, Sternberger LA, Sternberger NH, Strefling AM, Swanson K, Eng LF (1986) Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments. Neurosci Lett 64(3):253–258
122. Hill WD, Arai M, Cohen JA, Trojanowski JQ (1993) Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons. J Comp Neurol 329(3):328–336
123. Mersiyanova IV, Perepelov AV, Polyakov AV, Sitnikov VF, Dadali EL, Oparin RB et al (2000) A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 67(1):37–46
124. Brownlees J, Ackerley S, Grierson AJ, Jacobsen NJ, Shea K, Anderton BH et al (2002) Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. Hum Mol Genet 11(23):2837–2844
125. Perez-Olle R, Leung CL, Liem RK (2002) Effects of Charcot-Marie-Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation. J Cell Sci 115(Pt 24):4937–4946
126. Jordanova A, De Jonghe P, Boerkoel CF, Takashima H, De Vriendt E, Ceuterick C et al (2003) Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 126(Pt 3):590–597
127. Perez-Olle R, Lopez-Toledano MA, Goryunov D, Cabrera-Poch N, Stefanis L, Brown K et al (2005) Mutations in the neurofilament light gene linked to Charcot-Marie-Tooth disease cause defects in transport. J Neurochem 93(4):861–874
128. Fabrizi GM, Cavallaro T, Angiari C, Cabrini I, Taioli F, Malerba G et al (2007) Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton. Brain 130(Pt 2):394–403
129. Yoshihara T, Yamamoto M, Hattori N, Misu K, Mori K, Koike H et al (2002) Identification of novel sequence variants in the neurofilament-light gene in a Japanese population: analysis of Charcot-Marie-Tooth disease patients and normal individuals. J Peripher Nerv Syst 7(4):221–224
130. Fabrizi GM, Cavallaro T, Angiari C, Bertolasi L, Cabrini I, Ferrarini M et al (2004) Giant axon and neurofilament accumulation in Charcot-Marie-Tooth disease type 2E. Neurology 62(8):1429–1431
131. Georgiou DM, Zidar J, Korosec M, Middleton LT, Kyriakides T, Christodoulou K (2002) A novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics 4(2):93–96
132. Sasaki T, Gotow T, Shiozaki M, Sakaue F, Saito T, Julien JP et al (2006) Aggregate formation and phosphorylation of neurofilament-L Pro22 Charcot-Marie-Tooth disease mutants. Hum Mol Genet 15(6):943–952
133. Delisle MB, Carpenter S (1984) Neurofibrillary axonal swellings and amyotrophic lateral sclerosis. J Neurol Sci 63(2):241–250
134. Hirano A, Donnenfeld H, Sasaki S, Nakano I (1984) Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 43(5):461–470
135. Munoz DG, Greene C, Perl DP, Selkoe DJ (1988) Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol 47(1):9–18
136. Tu PH, Raju P, Robinson KA, Gurney ME, Trojanowski JQ, Lee VM (1996) Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A 93(7):3155–3160
137. Eyer J, Cleveland DW, Wong PC, Peterson AC (1998) Pathogenesis of two axonopathies does not require axonal neurofilaments. Nature 391(6667):584–587

138. Kong J, Xu Z (2000) Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis. Neurosci Lett 281(1):72–74
139. Couillard-Despres S, Zhu Q, Wong PC, Price DL, Cleveland DW, Julien JP (1998) Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci U S A 95(16):9626–9630
140. Beaulieu JM, Julien JP (2003) Peripherin-mediated death of motor neurons rescued by overexpression of neurofilament NF-H proteins. J Neurochem 85(1):248–256
141. Williamson TL, Bruijn LI, Zhu Q, Anderson KL, Anderson SD, Julien JP et al (1988) Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci U S A 95(16):9631–9636
142. Zhai Q, Wang J, Kim A, Liu Q, Watts R, Hoopfer E et al (2003) Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron 39(2):217–225
143. Erturk A, Hellal F, Enes J, Bradke F (2007) Disorganized microtubules underlie the formation of retraction bulbs and the failure of axonal regeneration. J Neurosci 27(34):9169–9180
144. Hall GF, Lee VM, Kosik KS (1991) Microtubule destabilization and neurofilament phosphorylation precede dendritic sprouting after close axotomy of lamprey central neurons. Proc Natl Acad Sci U S A 88(11):5016–5020
145. Cho Y, Cavalli V (2012) HDAC5 is a novel injury-regulated tubulin deacetylase controlling axon regeneration. EMBO J 31(14):3063–3078
146. Goldstein ME, Weiss SR, Lazzarini RA, Shneidman PS, Lees JF, Schlaepfer WW (1988) mRNA levels of all three neurofilament proteins decline following nerve transection. Brain Res 427(3):287–291
147. Oblinger MM, Lasek RJ (1988) Axotomy-induced alterations in the synthesis and transport of neurofilaments and microtubules in dorsal root ganglion cells. J Neurosci 8(5):1747–1758
148. Mikucki SA, Oblinger MM (1991) Corticospinal neurons exhibit a novel pattern of cytoskeletal gene expression after injury. J Neurosci Res 30(1):213–225
149. Tetzlaff W, Alexander SW, Miller FD, Bisby MA (1991) Response of facial and rubrospinal neurons to axotomy: changes in mRNA expression for cytoskeletal proteins and GAP-43. J Neurosci 11(8):2528–2544
150. Hoffman PN, Pollock SC, Striph GG (1993) Altered gene expression after optic nerve transection: reduced neurofilament expression as a general response to axonal injury. Exp Neurol 119(1):32–36
151. Hoffman PN, Lasek RJ (1980) Axonal transport of the cytoskeleton in regenerating motor neurons: constancy and change. Brain Res 202(2):317–333
152. Hoffman PN, Thompson GW, Griffin JW, Price DL (1985) Changes in neurofilament transport coincide temporally with alterations in the caliber of axons in regenerating motor fibers. J Cell Biol 101(4):1332–1340
153. McKerracher L, Essagian C, Aguayo AJ (1993) Temporal changes in beta-tubulin and neurofilament mRNA levels after transection of adult rat retinal ganglion cell axons in the optic nerve. J Neurosci 13(6):2617–2626
154. Jiang YQ, Pickett J, Oblinger MM (1994) Comparison of changes in beta-tubulin and NF gene expression in rat DRG neurons under regeneration-permissive and regeneration-prohibitive conditions. Brain Res 637(1–2):233–241
155. Park JY, Jang SY, Shin YK, Koh H, Suh DJ, Shinji T et al (2013) Mitochondrial swelling and microtubule depolymerization are associated with energy depletion in axon degeneration. Neuroscience 238:258–269
156. Tao J, Feng C, Rolls MM (2006) The microtubule-severing protein fidgetin acts after dendrite injury to promote their degeneration. J Cell Sci 129(17):3274–3281